Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Champions Oncology (CSBR) Research & Development (2016 - 2026)

Champions Oncology has reported Research & Development over the past 17 years, most recently at $2.3 million for Q1 2026.

  • Quarterly results put Research & Development at $2.3 million for Q1 2026, up 32.11% from a year ago — trailing twelve months through Jan 2026 was $8.9 million (up 29.22% YoY), and the annual figure for FY2025 was $6.8 million, down 28.49%.
  • Research & Development for Q1 2026 was $2.3 million at Champions Oncology, down from $2.6 million in the prior quarter.
  • Over the last five years, Research & Development for CSBR hit a ceiling of $3.2 million in Q1 2023 and a floor of $1.5 million in Q3 2024.
  • Median Research & Development over the past 5 years was $2.3 million (2026), compared with a mean of $2.3 million.
  • Biggest five-year swings in Research & Development: plummeted 47.94% in 2024 and later surged 54.88% in 2025.
  • Champions Oncology's Research & Development stood at $2.6 million in 2022, then dropped by 3.42% to $2.5 million in 2023, then tumbled by 32.84% to $1.7 million in 2024, then surged by 54.88% to $2.6 million in 2025, then fell by 13.19% to $2.3 million in 2026.
  • The last three reported values for Research & Development were $2.3 million (Q1 2026), $2.6 million (Q4 2025), and $2.1 million (Q3 2025) per Business Quant data.